Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of BI 765063 alone and with BI 754091 in advanced solid tumours
2024-519150-37-00Phase 2Completed
- Sponsor
- OSE Immunotherapeutics
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of BI 765063 and ezabenlimab in Nonhematologic neoplasms (2 arms), sponsored by OSE Immunotherapeutics. Primary endpoints: Safety and tolerability of BI 765063 alone and in combination with BI 754091, Pharmacokinetics of BI 765063 alone and in combination with BI 754091 and 2 more. Started Dec 2024; status: completed.
02
Drugs
BI 765063ezabenlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-519150-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519150-37-00.